Post-Certification Strategy (PCS) Update

Polio Partners Group

Note: Gavi requirements of $122.2 million are not included in this slide
Polio Eradication and Endgame Strategy

1. Poliovirus detection & interruption
2. OPV2 withdrawal, IPV introduction, immunization system strengthening
3. Containment & global certification
4. Transition Planning

Objectives:

- Mainstream polio-essential functions to sustain global eradication
- Support country transition planning
- Capture lessons learned

Focus of the Post-Certification Strategy
Post-certification Strategy (PCS)

Purpose: High-level guidance for maintaining a polio-free world after global certification of wild poliovirus eradication.

- Functions required to sustain polio eradication
  - Future risks jeopardizing eradication
  - Mitigating strategies
- Global/regional requirements and general country expectations
  - Does not provide detailed national guidance
- Recommendations independent of future ownership
  - Governance, implementation, and resource mobilization plans to be developed with future stakeholders
Assumptions at the time that PCS begins

• **Global eradication of all WPV will be certified** and all regions will have met the expected certification criteria for surveillance and immunity.

• The likelihood of poliovirus re-emergence will decrease with time, but the **seriousness of the consequences** of any re-emergence will **increase with time**.

• Detection of any poliovirus (WPV, VDPV, or Sabin >4 months after last use of mOPV or post-bOPV cessation) will have to be **reported to WHO under the International Health Regulations (2005) [IHR]** and will lead to the declaration of a national emergency and response.

• Sustaining **polio eradication** will be a **core objective of GVAP 2021-2030**.
Risks from poliovirus after certification

Polio Post-Certification Strategic Plan

Certification → bOPV Cessation

+1 year
Stage 1: Pre-Cessation

2-5 years
Stage 2: Immediate period

6-9 years
Stage 3: Intermediate period

Ongoing
Stage 4: Longer term period

Primary Risks

- Spread from immuno-compromised individuals to communities (iVDPV)
- VDPV emergence leading to cVDPV outbreaks
- Community circulation from containment breach (WPV, VDPV, Sabin)
**Purpose**: Sustain a polio-free world

| Goal 1: Contain Poliovirus Sources | ▪ Ensure potential sources of poliovirus are properly controlled or removed |
| Goal 2: Protect Populations | ▪ Withdraw the oral live attenuated polio vaccine (OPV) from use and immunize populations with inactivated polio vaccine (IPV) against possible re-emergence of any poliovirus |
| Goal 3: Detect and Respond | ▪ Promptly detect any poliovirus reintroduction and rapidly respond to prevent transmission |
PCS Timeline

- **Polio Eradication & Endgame Strategic Plan**
  - Interruption of transmission
  - Pre-certification
  - GPEI dissolution at certification

- **Post-Certification Strategy (10 years)**
  - Certification of eradication
  - Pre-cessation

- **Post-cessation**
  - Containment
  - Immunization
  - Vaccine management
  - Surveillance
  - Outbreak preparedness/response
  - Research

**Overlap period - GPEI & post-GPEI programmes (at least 12 months)**

**GPEI**
- Jan. 2018: WHO Exec. Board review - POB Approval of PCS
- May 2018: presentation to World Health Assembly

**Post-GPEI programmes**
- GPEI Dissolution at Certification
Thank you
Appendix
## Goal 1: Contain Polioviruses

<table>
<thead>
<tr>
<th>Objective(s)</th>
<th>Major Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achieve and sustain containment of polioviruses in laboratories, vaccine manufacturing and other facilities</td>
<td>• Support reduction of the global number of facilities storing poliovirus</td>
</tr>
<tr>
<td></td>
<td>• Monitor and sustain long-term poliovirus containment in facilities with appropriate safeguards</td>
</tr>
</tbody>
</table>
Goal 1: Summary of expectations

• **Global level**
  - Established Global Action Plan (GAPIII) to minimize risks of PV release from vaccine manufacturers or laboratories (including those with potentially infectious materials)
  - Global oversight to confirm containment/certification

• **Regional level**
  - Certification Commissions oversee progress

• **Country level**
  - Implement GAPIII guidelines;
  - Establish National Authority for Containment (NAC) if necessary to certify Polio Essential Facility (PEF)
## Goal 2: Protect Populations

<table>
<thead>
<tr>
<th>Objective(s)</th>
<th>Major Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>To protect populations from VAPP and VDPV by effectively preparing and implementing the globally synchronized withdrawal of bOPV</td>
<td>• Develop and implement plans (including pre-cessation SIAs) to withdraw bOPV from routine programmes and SIA</td>
</tr>
</tbody>
</table>
| To provide access to safe, effective vaccines for long-term protection from poliovirus for global populations | • Implement future immunization policy to protect population against poliovirus  
• Support the availability of affordable IPV vaccine and for effective, efficient delivery to facilitate high immunization coverage |
Goal 2: Summary of expectations

• Global level:
  ✓ GVAP establishes global coverage targets.
  ✓ SAGE recommends global polio vaccine policy;
  ✓ Collaboration of Gavi, GPEI, and other stakeholders to achieve availability of affordable supply of IPV

• Regional Level
  ✓ RITAG sets regional targets, provides regional guidance and monitors progress

• Country Level
  ✓ bOPV using countries: conduct pre-cessation SIAs; withdraw bOPV as part of globally synchronized plan and validate
  ✓ Sustain protection with IPV—particularly for high-risk countries/populations—requires strengthening RI as envisioned by GVAP and synergies with other VPD initiatives (e.g. MRI)
### Goal 3: Detect and Respond

<table>
<thead>
<tr>
<th>Main Objectives</th>
<th>Major Activities</th>
</tr>
</thead>
</table>
| Promptly detect any poliovirus in a human or in the environment through a sensitive surveillance system | • Redefine poliovirus surveillance paradigm  
• Sustain adequate and technically qualified laboratory and surveillance infrastructure (including human capacity) and information systems |
| Develop and maintain adequate global and regional capacity and resources to support national efforts to rapidly and effectively contain any new detected poliovirus and stop any new poliovirus transmission | • Identify future outbreak risks, develop response strategies and preparedness plans, and sustain trained human capacity to appropriately implement these strategies and plans  
• Create, maintain, and manage an adequate stockpile of polio vaccine and antivirals for an appropriate response |
Goal 3: Summary of expectations

• **Global / Regional levels:**
  - ✓ Provide TA, guidelines, monitoring, risk forecasting;
  - ✓ Support Global Polio Laboratory Network
  - ✓ Develop and maintain global stockpile of OPV/IPV and polio anti-viral drugs

• **Country level:**
  - ✓ Maintain minimum capacities for detection and response as required by IHR
  - ✓ Implement poliovirus specific surveillance w/ risk-based approach reflecting need for higher sensitivity in some areas and new systems to identify iVDPV excretors
  - ✓ Vision that AFP surveillance will be integrated with VPD or communicable disease surveillance